{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:26:31Z","timestamp":1785378391407,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10067-020-04963-2","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T23:02:49Z","timestamp":1580770969000},"page":"1039-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Obesity and its role in the management of rheumatoid and psoriatic arthritis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-9106","authenticated-orcid":false,"given":"Luca","family":"Moroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"2","key":"4963_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1467-789X.2009.00712.x","volume":"12","author":"D Withrow","year":"2011","unstructured":"Withrow D, Alter DA (2011) The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 12(2):131\u2013141. https:\/\/doi.org\/10.1111\/j.1467-789X.2009.00712.x","journal-title":"Obes Rev"},{"issue":"2","key":"4963_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/acr.22932","volume":"69","author":"Y Liu","year":"2017","unstructured":"Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2017) Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69(2):157\u2013165. https:\/\/doi.org\/10.1002\/acr.22932","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4963_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4963_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","volume":"8","author":"C Passot","year":"2016","unstructured":"Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D (2016) The underlying inflammatory chronic disease influences infliximab pharmacokinetics. mAbs 8(7):1407\u20131416. https:\/\/doi.org\/10.1080\/19420862.2016.1216741","journal-title":"mAbs"},{"issue":"6","key":"4963_CR5","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/JCI57132","volume":"121","author":"CN Lumeng","year":"2011","unstructured":"Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6):2111\u20132117. https:\/\/doi.org\/10.1172\/JCI57132","journal-title":"J Clin Invest"},{"issue":"10","key":"4963_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14656566.2016.1195812","volume":"17","author":"M Galluzzo","year":"2016","unstructured":"Galluzzo M, D'Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M (2016) Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother 17(10):1421\u20131433. https:\/\/doi.org\/10.1080\/14656566.2016.1195812","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"4963_CR7","doi-asserted-by":"publisher","first-page":"e2859","DOI":"10.1097\/MD.0000000000002859","volume":"95","author":"J Feng","year":"2016","unstructured":"Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, Cai Q, Liu Y, He J (2016) Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore) 95(8):e2859. https:\/\/doi.org\/10.1097\/MD.0000000000002859","journal-title":"Medicine (Baltimore)"},{"key":"4963_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-015-0601-x","volume":"17","author":"B Qin","year":"2015","unstructured":"Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q, Hu Z, Liang Y, Yang Z, Zhong R (2015) Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 17:86. https:\/\/doi.org\/10.1186\/s13075-015-0601-x","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4963_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/acr.21749","volume":"65","author":"A Wesley","year":"2013","unstructured":"Wesley A, Bengtsson C, Elkan AC, Klareskog L, Alfredsson L, Wedren S, Epidemiological Investigation of Rheumatoid Arthritis Study G (2013) Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res 65(1):107\u2013112. https:\/\/doi.org\/10.1002\/acr.21749","journal-title":"Arthritis Care Res"},{"issue":"11","key":"4963_CR10","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2014-205459","volume":"73","author":"B Lu","year":"2014","unstructured":"Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY, Awosogba JA, Arkema EV, Costenbader KH, Karlson EW (2014) Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 73(11):1914\u20131922. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205459","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4963_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/03009740802448825","volume":"38","author":"LA Rodriguez","year":"2009","unstructured":"Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA (2009) Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 38(3):173\u2013177. https:\/\/doi.org\/10.1080\/03009740802448825","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"4963_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"F Wolfe","year":"1994","unstructured":"Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481\u2013494. https:\/\/doi.org\/10.1002\/art.1780370408","journal-title":"Arthritis Rheum"},{"issue":"14","key":"4963_CR13","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/archinte.165.14.1624","volume":"165","author":"A Escalante","year":"2005","unstructured":"Escalante A, Haas RW, del Rincon I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165(14):1624\u20131629. https:\/\/doi.org\/10.1001\/archinte.165.14.1624","journal-title":"Arch Intern Med"},{"issue":"6","key":"4963_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/ard.2007.078832","volume":"67","author":"AH van der Helm-van Mil","year":"2008","unstructured":"van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67(6):769\u2013774. https:\/\/doi.org\/10.1136\/ard.2007.078832","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4963_CR15","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3899\/jrheum.150224","volume":"42","author":"C Vidal","year":"2015","unstructured":"Vidal C, Barnetche T, Morel J, Combe B, Daien C (2015) Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 42(12):2261\u20132269. https:\/\/doi.org\/10.3899\/jrheum.150224","journal-title":"J Rheumatol"},{"issue":"11","key":"4963_CR16","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1136\/annrheumdis-2014-206254","volume":"73","author":"N Ellerby","year":"2014","unstructured":"Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL (2014) Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 73(11):e74. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206254","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4963_CR17","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","volume":"73","author":"ME Sandberg","year":"2014","unstructured":"Sandberg ME, Bengtsson C, Kallberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S (2014) Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 73(11):2029\u20132033. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205094","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4963_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/acr.23457","volume":"70","author":"E Schulman","year":"2018","unstructured":"Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP, Investigators C (2018) Overweight, obesity, and the likelihood of achieving sustained remission in early rheumatoid arthritis: results from a multicenter prospective cohort study. Arthritis Care Res 70(8):1185\u20131191. https:\/\/doi.org\/10.1002\/acr.23457","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4963_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.21710","volume":"65","author":"S Ajeganova","year":"2013","unstructured":"Ajeganova S, Andersson ML, Hafstrom I, Group BS (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 65(1):78\u201387. https:\/\/doi.org\/10.1002\/acr.21710","journal-title":"Arthritis Care Res"},{"issue":"12","key":"4963_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3899\/jrheum.171232","volume":"45","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, MacCarter DK, Pangan AL, Wang X, Kalabic J, Ranganath VK (2018) Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate. J Rheumatol 45(12):1628\u20131635. https:\/\/doi.org\/10.3899\/jrheum.171232","journal-title":"J Rheumatol"},{"issue":"5","key":"4963_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10067-016-3220-2","volume":"35","author":"SK Kim","year":"2016","unstructured":"Kim SK, Choe JY, Park SH, Lee H (2016) No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. Clin Rheumatol 35(5):1129\u20131136. https:\/\/doi.org\/10.1007\/s10067-016-3220-2","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4963_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.30136","volume":"63","author":"R Klaasen","year":"2011","unstructured":"Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359\u2013364. https:\/\/doi.org\/10.1002\/art.30136","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4963_CR23","first-page":"478","volume":"33","author":"S Ottaviani","year":"2015","unstructured":"Ottaviani S, Gardette A, Tubach F, Roy C, Palazzo E, Gill G, Meyer O, Dieude P (2015) Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol 33(4):478\u2013483","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"4963_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","volume":"82","author":"S Ottaviani","year":"2015","unstructured":"Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E, Meyer O, Dieude P (2015) Body mass index and response to rituximab in rheumatoid arthritis. Joint Bone Spine 82(6):432\u2013436. https:\/\/doi.org\/10.1016\/j.jbspin.2015.02.011","journal-title":"Joint Bone Spine"},{"issue":"4","key":"4963_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","volume":"35","author":"A Gardette","year":"2016","unstructured":"Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Meyer A, Sibilia J, Fautrel B, Palazzo E, Dieude P (2016) Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 35(4):857\u2013861. https:\/\/doi.org\/10.1007\/s10067-016-3183-3","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4963_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3899\/jrheum.140673","volume":"42","author":"YM Pers","year":"2015","unstructured":"Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E, Mura T, Pallot-Prades B, Jorgensen C, Maillefert JF, Marotte H, Wendling D, Gaudin P (2015) Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 42(4):580\u2013584. https:\/\/doi.org\/10.3899\/jrheum.140673","journal-title":"J Rheumatol"},{"issue":"11","key":"4963_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","volume":"66","author":"A Kivitz","year":"2014","unstructured":"Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 66(11):1653\u20131661. https:\/\/doi.org\/10.1002\/acr.22384","journal-title":"Arthritis Care Res"},{"issue":"12","key":"4963_CR28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/eci.12691","volume":"46","author":"A Gardette","year":"2016","unstructured":"Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Fautrel B, Palazzo E, Meyer A, Sibilia J, Dieude P (2016) Body mass index and response to abatacept in rheumatoid arthritis. Eur J Clin Investig 46(12):1048\u20131052. https:\/\/doi.org\/10.1111\/eci.12691","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"4963_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jbspin.2016.10.011","volume":"84","author":"X Mariette","year":"2017","unstructured":"Mariette X, Alten R, Nusslein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M (2017) The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine 84(5):571\u2013576. https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.011","journal-title":"Joint Bone Spine"},{"issue":"12","key":"4963_CR30","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","volume":"36","author":"MA D'Agostino","year":"2017","unstructured":"D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G (2017) Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clin Rheumatol 36(12):2655\u20132665. https:\/\/doi.org\/10.1007\/s10067-017-3788-1","journal-title":"Clin Rheumatol"},{"key":"4963_CR31","doi-asserted-by":"publisher","unstructured":"Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A (2017) Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the \u201cpan-European registry collaboration for abatacept (PANABA). Clin Rheumatol 36 (4):773\u2013779. doi:https:\/\/doi.org\/10.1007\/s10067-016-3505-5","DOI":"10.1007\/s10067-016-3505-5"},{"issue":"1","key":"4963_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4963_CR33","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 173(6):1387\u20131399. https:\/\/doi.org\/10.1111\/bjd.14164","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"4963_CR34","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1111\/j.1529-8019.2009.01281.x","volume":"23","author":"F Bardazzi","year":"2010","unstructured":"Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A (2010) Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther 23(Suppl 1):S14\u2013S19. https:\/\/doi.org\/10.1111\/j.1529-8019.2009.01281.x","journal-title":"Dermatol Ther"},{"issue":"2","key":"4963_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162\u2013175. https:\/\/doi.org\/10.1177\/0091270008329556","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4963_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaci D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A (2016) A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273\u2013286. https:\/\/doi.org\/10.1111\/bjd.14493","journal-title":"Br J Dermatol"},{"issue":"7","key":"4963_CR37","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/jdv.14252","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C (2017) The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31(7):1196\u20131207. https:\/\/doi.org\/10.1111\/jdv.14252","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4963_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"MN di Minno","year":"2013","unstructured":"di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 65(1):141\u2013147. https:\/\/doi.org\/10.1002\/acr.21711","journal-title":"Arthritis Care Res"},{"issue":"1\u20132","key":"4963_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12026-014-8595-z","volume":"61","author":"L Costa","year":"2015","unstructured":"Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61(1\u20132):147\u2013153. https:\/\/doi.org\/10.1007\/s12026-014-8595-z","journal-title":"Immunol Res"},{"issue":"5","key":"4963_CR40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813\u2013817. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204448","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4963_CR41","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P Hojgaard","year":"2016","unstructured":"Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L (2016) The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology 55(12):2191\u20132199. https:\/\/doi.org\/10.1093\/rheumatology\/kew326","journal-title":"Rheumatology"},{"key":"4963_CR42","doi-asserted-by":"publisher","unstructured":"Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ (2019) Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.171034","DOI":"10.3899\/jrheum.171034"},{"issue":"9","key":"4963_CR43","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550\u20131558. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4963_CR44","doi-asserted-by":"publisher","first-page":"e000934","DOI":"10.1136\/rmdopen-2019-000934","volume":"5","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Ferraccioli G, D'Agostino MA, Le Bars M, Banerjee S, Ahmad HA, Elbez Y, Mease PJ (2019) Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open 5(1):e000934. https:\/\/doi.org\/10.1136\/rmdopen-2019-000934","journal-title":"RMD Open"},{"key":"4963_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2017.06.002","volume":"74","author":"J Rheinheimer","year":"2017","unstructured":"Rheinheimer J, de Souza BM, Cardoso NS, Bauer AC, Crispim D (2017) Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism 74:1\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2017.06.002","journal-title":"Metabolism"},{"issue":"11","key":"4963_CR46","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2174\/0929867324666170407123522","volume":"25","author":"R Mastrocola","year":"2018","unstructured":"Mastrocola R, Aragno M, Alloatti G, Collino M, Penna C, Pagliaro P (2018) Metaflammation: tissue-specific alterations of the NLRP3 inflammasome platform in metabolic syndrome. Curr Med Chem 25(11):1294\u20131310. https:\/\/doi.org\/10.2174\/0929867324666170407123522","journal-title":"Curr Med Chem"},{"key":"4963_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.phrs.2018.01.009","volume":"133","author":"G Medina","year":"2018","unstructured":"Medina G, Vera-Lastra O, Peralta-Amaro AL, Jimenez-Arellano MP, Saavedra MA, Cruz-Dominguez MP, Jara LJ (2018) Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res 133:277\u2013288. https:\/\/doi.org\/10.1016\/j.phrs.2018.01.009","journal-title":"Pharmacol Res"},{"issue":"5","key":"4963_CR48","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13(5):e0195123. https:\/\/doi.org\/10.1371\/journal.pone.0195123","journal-title":"PLoS One"},{"issue":"1","key":"4963_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76(1):17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4963_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","volume":"86","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J (2019) Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine 86(2):173\u2013183. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.007","journal-title":"Joint Bone Spine"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04963-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T02:29:05Z","timestamp":1612232945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04963-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4963"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04963-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"1 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}